Abstract
The central role of peroxisomes in ROS and lipid metabolism and their importance in brain functioning are well established. The aim of this work was to study the modulation of peroxisomal and peroxisome-related proteins in cortical neurons in vitro challenged with chronic or acute Aβ treatment, in order to investigate whether peroxisomes represent one of the cellular target of Aβ in these cells. The expression of peroxisomal (PMP70, catalase, acyl-CoA oxidase and thiolase), peroxisome-related (PPARα, insulin-degrading enzyme) and anti-oxidant (SOD1, SOD2, GSTP1) proteins was studied. The results obtained, demonstrating an early upregulation of the peroxisomal proteins during the chronic challenge, followed by their dramatic impairment after acute challenge, suggest that peroxisomes represent one of the first line of defence against Aβ-mediated oxidative injury. Our results support the notion that substances able to activate PPARα and/or to induce peroxisomal proliferation may constitute a novel preventive and/or therapeutic tool against neurodegenerative diseases.
Keywords: Neurodegeneration, lipid metabolism, anti-oxidant enzymes, PPARα
Current Alzheimer Research
Title: Neuronal Response of Peroxisomal and Peroxisome-Related Proteins to Chronic and Acute Aβ Injury
Volume: 6 Issue: 3
Author(s): A. Cimini, E. Benedetti, B. D'Angelo, L. Cristiano, S. Falone, S. Di Loreto, F. Amicarelli and M. P. Ceru
Affiliation:
Keywords: Neurodegeneration, lipid metabolism, anti-oxidant enzymes, PPARα
Abstract: The central role of peroxisomes in ROS and lipid metabolism and their importance in brain functioning are well established. The aim of this work was to study the modulation of peroxisomal and peroxisome-related proteins in cortical neurons in vitro challenged with chronic or acute Aβ treatment, in order to investigate whether peroxisomes represent one of the cellular target of Aβ in these cells. The expression of peroxisomal (PMP70, catalase, acyl-CoA oxidase and thiolase), peroxisome-related (PPARα, insulin-degrading enzyme) and anti-oxidant (SOD1, SOD2, GSTP1) proteins was studied. The results obtained, demonstrating an early upregulation of the peroxisomal proteins during the chronic challenge, followed by their dramatic impairment after acute challenge, suggest that peroxisomes represent one of the first line of defence against Aβ-mediated oxidative injury. Our results support the notion that substances able to activate PPARα and/or to induce peroxisomal proliferation may constitute a novel preventive and/or therapeutic tool against neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Cimini A., Benedetti E., D'Angelo B., Cristiano L., Falone S., Di Loreto S., Amicarelli F. and Ceru P. M., Neuronal Response of Peroxisomal and Peroxisome-Related Proteins to Chronic and Acute Aβ Injury, Current Alzheimer Research 2009; 6 (3) . https://dx.doi.org/10.2174/156720509788486518
DOI https://dx.doi.org/10.2174/156720509788486518 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Infectious Burden: A New Risk Factor and Treatment Target for Atherosclerosis
Infectious Disorders - Drug Targets Immunopharmacology of the Main Herbal Supplements: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Current State of Saliva Biomarkers for Aging and Alzheimer’s Disease
Current Alzheimer Research Editorial [Hot Topic: Cognition Therapeutics (Guest Editor: Miao-Kun Sun)]
Current Drug Targets - CNS & Neurological Disorders 1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology
Current Pharmaceutical Design Predicting Stability of Mild Cognitive Impairment (MCI): Findings of a Community Based Sample
Current Alzheimer Research BACE1 Levels by APOE Genotype in Non-Demented and Alzheimer’s Post-Mortem Brains
Current Alzheimer Research Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Novel Perspectives for Parkinson’s Disease Therapy: Insights from the Latest Advances in Disease Pathophysiology, Diagnostic and Experimental Tools and Molecular Targets)
CNS & Neurological Disorders - Drug Targets Arterial Wall Structure and Dynamics in Type 2 Diabetes Mellitus Methodological Aspects and Pathophysiological Findings
Current Diabetes Reviews Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology Carbon Monoxide and Iron Modulate Plasmatic Coagulation in Alzheimer’s disease
Current Neurovascular Research The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study
Current Alzheimer Research Evaluation of Post-Surgical Cognitive Function and Protein Fingerprints in the Cerebro-Spinal Fluid Utilizing Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass-Spectrometry (SELDI-TOF MS) After Coronary Artery Bypass Grafting: Review of Proteomic Analytic Tools and Introducing a New Syndrome
Current Medicinal Chemistry Endothelial Dysfunction Induced by Cadmium and Mercury and its Relationship to Hypertension
Current Hypertension Reviews Schiff Bases of Isatin: Inhibitory Potential Towards Acetylcholinesterase and Butyrylcholinesterase
Letters in Drug Design & Discovery